Metrosa

Metronidazole, the active ingredient in Metrosa, is a nitroimidazole antibiotic presented as a topical for topical use. It treats bacterial skin infections, rosacea and acne vulgaris in adults.

GNH USA supplies Metrosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metrosa is a nitroimidazole antibiotic used to manage skin conditions caused by susceptible anaerobic bacteria and inflammation.

Rosacea: reduces inflammatory lesions and erythema associated with the condition. Acne vulgaris: decreases papules, pustules and redness. Bacterial skin infections: eradicates susceptible organisms and promotes lesion healing.

Metrosa may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Skin irritation or burning sensation at the application site. - Itching or pruritus. - Dryness or peeling of the treated skin. - Redness or mild erythema.

Serious or Rare Side Effects: - Allergic reactions such as urticaria or angioedema. - Severe skin rash or Stevens‑Johnson syndrome. - Photosensitivity leading to exaggerated sunburn. - Contact dermatitis. - Systemic toxicity (rare) presenting as neurotoxicity or hepatic dysfunction.

Before using Metrosa, consider the following safety measures.

Pregnancy: Category B – use only if clearly needed after risk‑benefit assessment. Breastfeeding: Small amounts may be excreted in milk; evaluate necessity. Skin integrity: Avoid application on extensive open wounds or mucous membranes. Alcohol consumption: Limit intake to reduce risk of disulfiram‑like reaction. Allergy: Discontinue if signs of hypersensitivity develop. Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and direct light.

Metrosa can interact with several systemic medications; monitor patients accordingly.

Major Interactions (Avoid): - Alcohol: may cause a disulfiram‑like reaction with flushing and nausea. - Warfarin: can potentiate anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium levels, risking toxicity. - Cimetidine: may increase metronidazole plasma concentrations.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy, consider alternative contraception. - Phenobarbital: may lower metronidazole levels, potentially reducing effectiveness.